Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Hu Q, Poulose N, Girmay S, Helevä A, Doultsinos D, Gondane A, et al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biol. 2021:1-8.

Martini R, Chen Y, Jenkins BD, Elhussin IA, Cheng E, Hoda SA, et al. Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort. Sci Rep. 2021;11(1):9247.

Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).

Patel SS. Pediatric Myelodysplastic Syndromes. Clin Lab Med. 2021;41(3):517-528.

Panza E, Vellecco V, Iannotti FA, Paris D, Manzo OL, Smimmo M, et al. Duchenne's muscular dystrophy involves a defective transsulfuration pathway activity. Redox Biol. 2021;45:102040.

Fine SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, et al. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urol Oncol. 2021;39(5):295.e1-295.e8.

Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021;34(3):108638.

Kung A, Chen J, Tomasek M, Liu D, Rodgers W, Gau V. Transportation protocols for accurate assessment of microbial burden classification using molecular methods. Sci Rep. 2021;11(1):16069.

Linares JF, Zhang X, Martinez-Ordoñez A, Duran A, Kinoshita H, Kasashima H, et al. PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. Mol Cell. 2021.

Miltiadous O, Petrova-Drus K, Kaicker S, Mathew S, Kluk M, Geyer JT, et al. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. Blood Adv. 2021.